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Abstract Nuclear import of simian virus SV40 large tumour
antigen (T-ag) is enhanced by the protein kinase CK2 (CK2) site
flanking the nuclear localisation sequence (NLS). We report here
that replacement of this site with a consensus site for protein
kinase C (PK-C) can alter the regulation of T-ag nuclear import
and render it inducible by phorbol ester. Measurement of nuclear
import kinetics using fluorescently labelled proteins and confocal
laser scanning microscopy show that the introduced PK-C site is
functional in enhancing T-ag nuclear import compared to a
protein lacking the CK2 site. Treatment with the PK-C activator
phorbol 12-myristate 13-acetate (PMA) further increases the
level of maximal nuclear accumulation and the initial nuclear
import rate. This engineered PMA-responsive NLS may have
application in targeting of molecules of interest to the nucleus in
response to agents stimulating PK-C.
z 1998 Federation of European Biochemical Societies.
Key words: Ca2/phospholipid-dependent protein kinase C;
Nuclear import kinetics ; Confocal laser scanning microscopy;
Microinjection; Phosphorylation-regulated nuclear
localization sequence
1. Introduction
Proteins larger than 45 kDa conventionally require a nu-
clear localisation sequence (NLS) in order to enter the nucleus
[1,2]. NLS-dependent nuclear import of the simian virus SV40
large tumour antigen (T-ag), however, is regulated through
action of the modular CcN motif [3,4], comprising phospho-
rylation sites for protein kinase CK2 (CK2) and cyclin-de-
pendent kinase (cdk) together with the NLS. The rate of T-
ag nuclear import is enhanced 50-fold by the CK2 phospho-
rylation site (Ser111=112) [3,5^7], whilst phosphorylation at the
cdk site (Thr124) adjacent to the NLS (amino acids 126^132)
determines the maximal extent of nuclear accumulation [3].
CcN motifs also appear to mediate regulated nuclear import
of the yeast transcription factor SWI5 [8,9] and the Xenopus
nuclear phosphoprotein nucleoplasmin [10].
In analogous fashion to T-ag and SWI5, many proteins
contain phosphorylation sites close to their NLSs which reg-
ulate NLS activity, the sites together with the NLSs thus
constituting modular phosphorylation-regulated NLSs
(prNLSs) [1,2] able to confer regulated nuclear import on
heterologous proteins [3,9]. prNLSs can be divided into
classes where phosphorylation either enhances or inhibits
NLS function [1,2], with the CcN motif as a specialised type
of prNLS containing both enhancing and inhibitory phos-
phorylation sites. CK2 and cdk are not the only kinases reg-
ulating protein nuclear import [1,2,7] ; the cAMP-dependent
protein kinase (PK-A), for example, has been shown to en-
hance nuclear import of the Drosophila melanogaster morph-
ogen Dorsal [11,12], whilst phosphorylation by Ca2/phos-
pholipid-dependent protein kinase C (PK-C) inhibits nuclear
import of lamin B2 [13]. A variety of hormonal or other sig-
nals can thus a¡ect the inhibition or enhancement of nuclear
localisation of proteins carrying prNLSs [1], where the nature
of the kinase site(s) within the prNLS determines which spe-
ci¢c signals can modulate nuclear import.
To test whether substituting a kinase site by another could
alter the signals regulating nuclear import and as a ¢rst step
toward developing a prNLS capable of conferring inducible
nuclear translocation on other molecules of interest, we re-
cently substituted the T-ag CK2 site by a consensus phospho-
rylation site for PK-A [14]. The resultant protein exhibited
PK-A-mediated enhancement of nuclear import [14], which
could have been attributable to the fact that PK-A appears
to play an exclusively enhancing role on nuclear transport in
the case of a number of other proteins [1,11,15]. We decided
to investigate this further by substituting the T-ag CK2 site
with a consensus site for PK-C, reported to regulate nuclear
import negatively [1,13]. We show that the resultant fusion
protein can be speci¢cally phosphorylated by puri¢ed PK-C
in vitro, and determine its nuclear import kinetics in HTC rat
hepatoma tissue cells in the absence and presence of phorbol
12-myristate 13-acetate (PMA), an activator of PK-C [16^18],
using confocal laser scanning microscopy (CLSM). Somewhat
surprisingly, all results indicate that the PK-C site enhances
T-ag nuclear import, implying that it is the position of the
phosphorylation site relative to the NLS, rather than the na-
ture of the kinase phosphorylating it, that determines whether
the site can enhance or inhibit nuclear import. The PMA-
responsive prNLS derived and characterised here may have
application in targeting molecules of interest to the nucleus in
a clinical or research context.
2. Materials and methods
2.1. Chemicals
Puri¢ed PK-C (rat brain) was from Promega, recombinant human
CK2 from Boehringer Mannheim, DL-dithiothreitol (DTT) and PMA
from Sigma, and 5-iodoacetamido£uorescein (IAF) from Molecular
Probes. Other reagents were from the sources described previously
[14,19].
2.2. Cell culture
Cells of the HTC rat hepatoma tissue culture cell line, a derivative
of Morris hepatoma 7288C, were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 10% foetal calf serum
[3,6].
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2.3. T-ag L-galactosidase fusion proteins
The T-ag L-galactosidase fusion proteins used in this study are
shown in Fig. 1A. They contain T-ag amino acid residues 111^135,
including the CcN motif (comprising CK2 and cdk phosphorylation
sites and NLS), or variants thereof, fused N-terminal to the Esche-
richia coli L-galactosidase sequence (amino acids 9^1023, EC
3.2.1.23.37) (see [3,5^7]). Oligonucleotide site-directed mutagenesis
(Clontech Transformer Kit) of plasmid pDAJ2 (see [7]), performed
as previously [14], was used to substitute a consensus site for PK-C
(Arg-Gly-Ser-Ser111-Ser-Arg) in place of the CK2 site (Ser111-Ser112-
Asp-Asp-Glu). Integrity of the constructs was con¢rmed by DNA
sequencing.
2.4. Fusion protein expression, puri¢cation and labelling
Isopropyl-L-D-thiogalactopyranoside (1 mM) was used to induce
fusion protein expression in E. coli strain MC1060 [20]. Proteins
were puri¢ed by a⁄nity chromatography and labelled with IAF as
described [6].
2.5. Nuclear import kinetics
Analysis of nuclear import kinetics at the single cell level using
either microinjected (in vivo) or mechanically perforated (in vitro)
HTC cells in conjunction with CLSM (Bio-Rad MRC-600) was as
described previously [3,6,7,9]. In the case of in vivo experiments,
HTC cells were fused with polyethylene glycol (PEG 1500) at least
1 h prior to microinjection to produce polykaryons [5,6]. Nuclear
import of PKC-cN-L-Gal was measured with or without treatment
with PMA carried out either by coinjecting with 200 ng/ml PMA in
the injection pipette, or preincubating cells with 20 ng/ml PMA for 4 h
before injection. cAMP (25 WM in the injection pipette) was also
coinjected as a negative control [14]. Image analysis of CLSM ¢les
using the NIH Image public domain software and curve ¢tting were
as described [9,14].
2.6. In vitro phosphorylation
In vitro phosphorylation of fusion proteins by CK2 was analysed as
previously by SDS gel electrophoresis, and the stoichiometry of phos-
phorylation determined where appropriate [7,14,21,22]. Phosphoryla-
tion by PK-C was performed using 1^1.5U1033 unit/Wl PK-C, 1 mg/
ml fusion protein or histone H1 in a reaction bu¡er containing 20 mM
HEPES (pH 7.4), 1 mM DTT, 10 mM MgCl2 and 0.2 mM ATP
(containing 0.05 WM Q-[32P]ATP) in the presence of 200 Wg/ml phos-
phatidyl serine and 1 mM CaCl2 for 30^60 min at 30‡C [23], followed
by gel electrophoresis and phosphorimaging [24].
3. Results
3.1. An engineered PK-C site in place of the T-ag CK2 site
A consensus PK-C phosphorylation site (see Fig. 1A) was
introduced into the T-ag CcN motif in place of the CK2 site
using site-directed mutagenesis. To show functionality of the
site, in vitro phosphorylation was performed using puri¢ed
CK2 and PK-C (Fig. 1B). In contrast to the wild type CcN-
L-Gal T-ag fusion protein (stoichiometry of phosphorylation
of 1.1 mol Pi/mol tetrameric fusion protein), the engineered
PKC-cN-L-Gal fusion protein was not phosphorylated by
CK2 (Fig. 1B), indicating that the CK2 site was no longer
functional. PKC-cN-L-Gal was, however, able to be speci¢-
cally phosphorylated by PK-C (Fig. 1B; phosphorylation lev-
els almost 6-fold those of cN-L-Gal, lacking a PK-C site at the
CK2 site position ^ see Fig. 1A), indicating functionality of
the introduced PK-C site. The wild type CcN-L-Gal fusion
protein was not phosphorylated by PK-C to any signi¢cant
extent (not shown), while L-galactosidase itself was not phos-
phorylated by PK-C at all (Fig. 1B). The results indicated that
a PK-C site had been successfully introduced in place of the
CK2 site in the T-ag CcN motif.
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Fig. 1. Sequence of the T-ag fusion proteins used in this study and
speci¢c CK2 and PK-C phosphorylation in vitro. A: All proteins
contain T-ag sequences, shown in capital letters, fused N-terminal
to E. coli L-galactosidase (amino acids 9^1023). Linker and mutated
sequences are shown in small letters. The single letter amino acid
code is used, with the T-ag-NLS double underlined, phosphorylation
sites in bold, the CK2 site underlined and the PK-C site underlined
with a dotted line. The consensus site for PK-C phosphorylation
created in PKC-cN-L-Gal is Arg-X-X-Ser-X-Arg, where X is any
amino acid, and Ser is the site of phosphorylation. B: T-ag fusion
proteins were phosphorylated using either CK2 or PK-C as indi-
cated at 30‡C for 30^60 min prior to analysis by gel electrophoresis
and autoradiography. Histone H1 was used as a positive control for
PK-C phosphorylation.
Table 1
Nuclear import kinetics of SV40 T-ag fusion proteins in the presence and absence of various treatments
Fusion proteina Kinase sites Treatment Nuclear import parameterb
CK2 PK-C in vivo in vitro
Fn/cmax Initial ratec Fn/cmax k (1033)
Fn/c/min
cN-L-Gal 3 3 1.65 þ 0.05 NDd 1.43 þ 0.03 (1) NDd
CcN-L-Gal + 3 5.87 þ 0.19 1.14 þ 0.27 (4) 6.95 þ 0.60 (3) 35 þ 5
PKC-cN-L-Gal 3 + 2.15 þ 0.07 0.57 þ 0.08 (3) 3.98 þ 0.39 (3) 52 þ 10
PKC-cN-L-Gal 3 + PMA (in medium) 3.04 þ 0.19 0.63 þ 0.13 (2)
PKC-cN-L-Gal 3 + PMA (coinjected) 3.07 þ 0.24 0.72 þ 0.10 (2)
PKC-cN-L-Gal 3 + cAMP (coinjected) 1.92 þ 0.12 0.47 þ 0.14 (2)
aT-ag fusion protein sequences are presented in Fig. 1A.
bRaw data (see Fig. 2Fig. 3) were ¢tted as described in the legend to Fig. 2 and represent the mean þ S.E.M. (n in parentheses).
cThe initial rate represents the initial nuclear import rate determined up to 3 min after microinjection.
dND, not determined.
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3.2. The introduced PK-C site enhances T-ag nuclear import
The kinetics of nuclear import of PKC-cN-L-Gal were com-
pared to those of the wild type CcN-L-Gal T-ag fusion pro-
tein, as well as a derivative lacking a functional CK2 site (cN-
L-Gal) [6] (see Fig. 1A for T-ag sequences), both in vivo and
in vitro (Figs. 2 and 3A). PKC-cN-L-Gal showed maximal
nuclear accumulation about 30 and 60% that of the wild
type CcN-L-Gal in vivo and in vitro respectively, well above
that of cN-L-Gal, lacking a functional phosphorylation site at
the CK2 site position (Figs. 2 and 3A; Table 1). The fact that
PKC-cN-L-Gal accumulated e⁄ciently in the nucleus of HTC
cells both in vivo and in vitro indicated that the PK-C site is
functional in enhancing T-ag nuclear import in the absence of
agents stimulating PK-C activation, presumably attributable
to phosphorylation at the site stemming from basal PK-C
activity [14].
3.3. Induction of PK-C activity enhances nuclear import
Nuclear import of PKC-cN-L-Gal was assessed in vivo in
response to treatment with the PK-C activator PMA (Fig. 3
and Table 1), administered either by coinjection, or preincu-
bation of the cells for 4 h prior to microinjection. In contrast
to coinjection with cAMP as a negative control, PMA treat-
ment increased the maximal level of nuclear accumulation of
PKC-cN-L-Gal by about 40%, and the initial import rate by
20% (Fig. 3A,B; Table 1). PMA had a negligible e¡ect on
nuclear import of CcN-L-Gal containing the wild type CK2
site (not shown), and this, together with the lack of an e¡ect
of cAMP on PKC-cN-L-Gal nuclear import (Fig. 3B and
Table 1), underlined the speci¢city of the PMA e¡ect on nu-
clear import of PKC-cN-L-Gal. The results thus indicate that
nuclear import of PKC-cN-L-Gal can be enhanced by PMA
treatment in terms of both maximal nuclear accumulation and
initial nuclear import rate, through increased PK-C-mediated
phosphorylation at the engineered site.
4. Discussion
We have previously shown that a PK-A site in place of the
T-ag CK2 site can enhance nuclear import of a heterologous
protein in response to PK-A activation [14]. Here we show
that an engineered PK-C site £anking the T-ag NLS can also
enhance nuclear import, despite the fact that PK-C has been
shown to inhibit nuclear import of proteins such as lamin B2
[1,13]. Nuclear accumulation of PKC-cN-L-Gal in vivo and in
vitro was 30 and 60% respectively that of the wild type CK2
site-containing protein, signi¢cantly higher than that of a pro-
tein lacking a functional phosphorylation site at the CK2 site
position, indicating that the engineered PK-C site is functional
in enhancing T-ag nuclear import. Treatment with the PK-C
activator PMA further increased the initial nuclear import
rate and the maximal nuclear accumulation, consistent with
PK-C-mediated enhancement of nuclear import. Clearly, a
functional PMA-responsive PK-C site can enhance T-ag fu-
sion protein nuclear import in similar fashion to the wild type
CK2 phosphorylation site. That the enhancing e¡ect of the
PK-C site on nuclear import was not absolutely dependent on
PMA treatment (see Fig. 2) is attributable to phosphorylation
at the PK-C site through basal cytosolic PK-C activity (see
[14]). This means that, at least in HTC cells, the engineered
prNLS does not appear to be completely dependent on exog-
enous stimulation for nuclear targeting activity (see also [14]).
As mentioned above, all results indicate that the engineered
PK-C site enhances T-ag nuclear import, even though PK-C
has previously been reported to inhibit rather than enhance
nuclear import [1,13]. The PK-C site in PKC-cN-L-Gal was
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Fig. 2. Nuclear import kinetics in vivo (left) and in vitro (right). Nuclear import was measured in HTC cells using CLSM and image analysis
as described in Section 2. Results represent the average of at least two separate experiments, where each point represents the average of 6^10
separate measurements for each of nuclear (Fn) and cytoplasmic (Fc) £uorescence, respectively, with auto£uorescence subtracted. Curves were
¢tted for the function Fn/c (t) = Fn/cmax (13e3kt) [9,14], where Fn/cmax is the maximal nuclear accumulation level, k is the nuclear import rate
constant, and t is time in minutes [3,6,7].
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placed in the position of the nuclear import enhancing T-ag
CK2 site, implying that rather than the exact nature per se of
the kinase phosphorylating within a prNLS being important,
it is the position of its site relative to the NLS that determines
whether it enhances or inhibits NLS function. This is com-
pletely consistent with our recent ¢ndings [19,24] with respect
to the mechanism of CK2 enhancement of T-ag nuclear im-
port, which appears to be through direct involvement of the
residues of the CK2 site in mediating interaction with the
NLS-binding importin K subunit ; negative charge through
phosphorylation at the CK2 site increases the a⁄nity of the
interaction with importin K, whilst altering the distance be-
tween the CK2 site and NLS reduces the binding a⁄nity [19].
By analogy, it seems reasonable to postulate that negative
charge at the PK-C site through PMA-induced or basal PK-
C activity in the case of PKC-cN-L-gal is the mechanism by
which the site enhances nuclear import; altering the sequence,
but not the position, of the kinase site simply alters the nature
of the cellular signals that can enhance nuclear import.
Whether the introduction of a consensus site for another kin-
ase (e.g. for the nuclear import enhancing PK-A) in place of
the T-ag CcN motif cdk site, which inhibits T-ag nuclear im-
port, can alter the signals which inhibit T-ag nuclear import
(eg. make them cAMP-dependent in the case of a PK-A site)
is currently under investigation.
Engineered prNLSs such as that described here where PK-C
or PK-A sites enhance nuclear import are of particular inter-
est since they potentially confer tightly regulated nuclear lo-
calisation according to hormonal or other stimuli, thus ena-
bling precise cuing of the nuclear entry of relevant proteins
and other molecules according to need [14]. This may have
application in facilitating the directed transport of DNA mol-
ecules encoding a gene of interest to the nucleus of relevant
cells to increase transfection and/or homologous recombina-
tion e⁄ciencies, or to correct inborn errors of metabolism in
gene therapy [25,26]. Alternatively, engineered prNLSs can be
used to deliver drugs to the nucleus; agents that might be used
in this context include anti-cancer drugs or photosensitiser
molecules for which the nucleus is a hypersensitive site. Con-
jugates to which variants of the T-ag CcN motif were linked
in order to target the photosensitiser chlorin e6 to the nucleus
[27], for example, have been shown to increase photosensitis-
ing activity up to 2000-fold. The prNLSs derived and charac-
terised in this and previous [14] studies thus represent an
important step towards developing a signal conferring induc-
ible nuclear targeting of molecules of interest.
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